Rare liver growth meets pipeline regulatory delays
- Mirum raised full year 2026 revenue guidance to $680 million to $700 million after strong LIVMARLI demand.
- LIVMARLI is the main engine, with PFIC uptake in an estimated 2,000 adult patients driving the latest raise.
- The company faced a regulatory setback when the FDA recommended a Phase 3 trial for volixibat in PSC, delaying the NDA submission.
- New assets add upside, including brelovitug for HDV and zilurgisertib for FOP, but they also add integration risk.
- Management expects operating cash flow to turn positive in 2027, while GAAP profitability is now expected in 2028.
Growth is real, patience is required
Mirum has moved from a single rare liver story into a broader rare disease company. Its core drug, LIVMARLI, treats severe itching tied to rare liver diseases. The bull case is simple. The company needs to keep finding more eligible patients, keep payers covering the drug, and use the same liver doctor network to launch more products.
The commercial setup is strengthening. Management raised full year 2026 revenue guidance to $680 million to $700 million, helped by PFIC demand. The company estimates an addressable adult PFIC population of at least 2,000 patients in the United States. It expanded its U.S. field team to about 60 people to reach more than 4,000 liver health care professionals.
The pipeline gives Mirum several ways to grow beyond today's sales, but it carries risk. Brelovitug adds chronic HDV, a serious viral hepatitis market. Zilurgisertib, if approved for FOP, could become a new rare genetic disease business. However, volixibat faced a setback in PSC when the FDA recommended an additional Phase 3 trial, delaying the planned NDA submission to the first half of 2027.
The bear case centers on execution and time. Rare disease markets are small, launches can stall if adult doctors do not adopt quickly, and recent deals add cost before they add revenue. The volixibat delay highlights regulatory risks. Management still expects operating cash flow to turn positive in 2027, but GAAP profitability is pushed to 2028 because research spending stays heavy.
Selling scarce medicines to small markets
Mirum makes money by selling approved medicines for rare diseases. These are not mass market drugs. They are aimed at small patient groups where treatment options are limited and pricing can be high if insurers agree the drug matters.
The company sells directly in the United States and some European countries. In other places, it uses partners and distributors. Takeda, for example, handles LIVMARLI in Japan under a licensing and supply deal.
This model can be powerful once a medicine is approved. Sales teams can target a clear group of specialists, and a small number of diagnosed patients can still support large revenue. The weak point is that every patient matters. If diagnosis, reimbursement, safety, or doctor education slips, growth can slow fast.
Mirum also buys or licenses assets to widen its base. That can speed growth, but it raises the bill for research, milestones, royalties, and commercial buildout. The Bluejay deal brought brelovitug, while the Incyte deal brought rights to commercialize zilurgisertib if approved.
Approved drugs and bought options
LIVMARLI
LIVMARLI is approved for cholestatic pruritus in Alagille syndrome and PFIC. It is Mirum's largest product and the main reason management raised 2026 guidance.
Cholbam and Ctexli
Cholbam treats bile acid synthesis disorders, and Ctexli treats adults with CTX. Mirum groups these as bile acid medicines in its revenue table.
Volixibat
Volixibat is being advanced for PSC and PBC. The FDA recently recommended a Phase 3 trial for PSC, delaying the planned NDA submission to the first half of 2027.
Brelovitug
Brelovitug targets chronic hepatitis D virus. AZURE-1 and AZURE-4 topline results are expected in the second half of 2026.
Zilurgisertib
Mirum acquired rights from Incyte to commercialize zilurgisertib if approved for fibrodysplasia ossificans progressiva. The FDA action date is September 26, 2026.
MRM-3379
MRM-3379 is an oral CNS-penetrant PDE4D inhibitor for Fragile X syndrome. It expands Mirum beyond liver and bile acid disease into neurocognitive disorders.
One segment, two sales buckets
Mirum says it manages the company as one operating segment. For Q1 2026 product sales, LIVMARLI produced $113.804 million and bile acid medicines produced $46.078 million, out of $159.882 million total product sales.
What could break the story
Adult PFIC launch slows
High impact · Medium oddsThe 2026 guidance raise depends on strong LIVMARLI demand, including an estimated 2,000 adult PFIC patients. Mirum expanded its field team to reach adult liver care settings, but hiring reps does not guarantee prescriptions. If adult hepatologists do not adopt LIVMARLI quickly, the growth story weakens.
Reimbursement or pricing pressure
High impact · Medium oddsRare disease drugs often depend on high prices and broad insurance coverage. Mirum must keep payers convinced that its approved medicines are worth covering. More denials, bigger rebates, or tougher government pricing could reduce net sales.
Pipeline catalysts disappoint or delay
High impact · Medium oddsA lot of the upside sits in the pipeline. The FDA already recommended an additional Phase 3 trial for volixibat in PSC, delaying the NDA. A negative outcome for brelovitug AZURE data, or a zilurgisertib rejection would cut future growth hopes further.
Deal integration and spending run hot
Medium impact · Medium oddsMirum has added assets through deals, including Bluejay and the Incyte commercial rights. These moves bring new science, new teams, new obligations, and new launch work. The company already pushed GAAP profitability to 2028 because research spending remains heavy.
Supply and channel concentration
Medium impact · Low oddsMirum relies on a single third-party logistics provider and a single specialty pharmacy for all sales of approved medicines in the United States and Canada. That makes distribution simpler, but it creates a bottleneck. A service failure could disrupt patient access and reported sales.
In one breath
What does Mirum Pharmaceuticals do?
Mirum sells medicines for rare diseases, mainly rare liver and bile acid disorders. Its biggest product is LIVMARLI, which treats severe itching linked to Alagille syndrome and PFIC.
Why is LIVMARLI so important to MIRM stock?
LIVMARLI is the main growth driver today. Strong PFIC demand helped management raise full year 2026 revenue guidance to $680 million to $700 million.
When could Mirum become profitable?
Management expects operating cash flow to turn positive in 2027. GAAP profitability, which includes more accounting costs and heavy research spending, is expected in 2028.
What are the next big Mirum catalysts?
Key events include AZURE trial results for brelovitug in the second half of 2026, the September 26, 2026 FDA action date for zilurgisertib, and a planned volixibat NDA submission now delayed to the first half of 2027.
